Navigation Links
Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study
Date:12/15/2009

NASHVILLE, Tenn., Dec. 15 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. ( CPIX) today announced new top-line results for a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to similar products in liquid forms.

Kristalose is the only prescription-strength laxative available in pre-measured powder packets. Over a 14-day period, 50 patients with a recent diagnosis of chronic constipation were administered both Kristalose and liquid lactulose in a crossover study. Patient preference was measured through survey responses collected at the end of the study.

"Patients think that Kristalose tastes better and is more convenient than other options, which means that they are more likely to take the medication as directed," notes one investigator for the study, Charles F. Barish, MD, President of Wake Research Associates in Raleigh, North Carolina and Clinical Assistant Professor of Medicine at the University of North Carolina School of Medicine. "It makes sense to prescribe medications that encourage patient compliance with the treatment protocol."

Overall, more patients preferred Kristalose, noting portability as a key differentiating feature, as Kristalose is distributed in pre-measured packets. More patients also preferred the taste of Kristalose as well as the consistency compared to the syrup formulations.

"We have believed for some time that patients prefer taking Kristalose over other alternatives in liquid and syrup forms," said A.J. Kazimi, Chief Executive Officer at Cumberland Pharmaceuticals. "This study also offers data demonstrating the importance of convenience for these patients, which Kristalose can provide."

There was no significant difference in adverse effects between patients who took Kristalose and those taking liquid lactulose.

Backgrou
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc.
2. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
5. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
6. AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate
7. Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM)
8. Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments
9. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
10. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
11. GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... LONDON , May 6, 2015 ... HIV maintenance therapy with dolutegravir and rilpivirine ... start of a Phase III clinical trial programme ... (Tivicay®) and rilpivirine (Edurant® [1] ) as maintenance ... III programme comprises two replicate studies evaluating 48 ...
(Date:5/6/2015)... , May 6, 2015   Wilson Therapeutics ... CEO Jonas Hansson has been invited to ... the annual BioEquity Conference, this year to be held ... May 19 th . About WTX101 ... is currently in Phase 2 testing for Wilson Disease. ...
(Date:5/6/2015)... , May 6, 2015 ... join the Wellcome Trust and the Bill & ... Kymab, a leading monoclonal antibody biopharmaceutical ... an additional US$50 million to complete a US$90 ... being invested by Woodford Patient Capital Trust plc ...
Breaking Medicine Technology:ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10Wilson Therapeutics To Present As A "Next Wave" Company During BioEquity 2015 Conference In Vienna On May 19th 2Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... March 31, 2012, on Thursday, May 10, 2012, following the ... an investor conference call and live webcast to discuss the ... Eastern Time / 2:00 p.m. Pacific Time on the same ...
... 2012 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI") ... today announced the signing of expanded strategic technology ... agreements, TDI now has the right to use ... Platform for their planned entry into the clinical ...
Cached Medicine Technology:Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 2Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 3Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 2Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 3Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 4Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 5Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 6
(Date:5/6/2015)... Launch Corporation, LLC. is pleased to announce that Launch Trampoline ... Tanguay Avenue. Owned and operated by Rick Arnold and Phil ... New England. , “We are extremely excited for Rick and ... and CEO of Launch. “They have established great roots in ... continue to establish that positive growth in the greater Nashua ...
(Date:5/6/2015)... May 06, 2015 The SGNY Group ... York City, announced today that it was named a ... a presentation video produced on behalf of Intarcia Therapeutics. ... category of motion graphics. , The competition sponsored by ... over 6000 entries from 22 countries. The competition ...
(Date:5/5/2015)... 06, 2015 It’s not your usual Veterans ... their classic cars and motorcycles to the 3rd Annual “Crusin ... 8 p.m. at the Lincoln VA Clinic, 600 S. 70th ... to check out each other’s rides, but also to talk ... and services. , Staff from the VA Nebraska-Western Iowa ...
(Date:5/5/2015)... Private equity consultant and international research ... that its dental stem cell biobank project, Provia ... April, 2015 –and posted yet another exciting record. This ... and represents a significant 54% increase over last April ... is conducted via the Store-A-Tooth brand. The company has ...
(Date:5/5/2015)... “Given that Hispanics are one in six people ... are a major step in the arsenal of facts documenting ... past 30 years, data have accumulated that the health of ... the urgency and the need to create new models of ... all,” said Jane L. Delgado, PhD, MS, President and CEO ...
Breaking Medicine News(10 mins):Health News:Jump Up and Celebrate: Launch Trampoline Park Opens in Nashua, NH 2Health News:The SGNY Group Wins Platinum Hermes Creative Award 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2
... the brain could play a key role in regulating ... plaques implicated in the development of Alzheimer,s disease, according ... A group led by Domenico Pratico, professor of pharmacology ... of the protein, called 12/15-Lipoxygenase, in the brain three ...
... News) -- Researchers who found the earliest known ... the evolution of complex reproductive behavior in early dinosaurs. ... million years older than previously known nesting sites. It ... Massospondylus , a relative of the giant, long-necked sauropods ...
... (HealthDay News) -- Researchers who identified a protein that ... eventually lead to new treatments for the neurodegenerative disease. ... in neurons in the striatum, the part of the ... Parkinson,s disease in mice, the researchers found that RGS4 ...
... a genetic outlier, which has prevented scientists from discovering the ... Health and Yale University School of Medicine have devised a ... , the major cause of human malaria. This new approach ... and opens the door to further genetic discovery for the ...
... Calif. (January 25, 2012) Gardasil, the human papillomavirus ... adolescents and young adults, does not trigger autoimmune conditions ... multiple sclerosis after vaccination in young women, according to ... Medicine . Kaiser Permanente researchers used electronic health ...
... , WEDNESDAY, Jan. 25 (HealthDay News) -- Learning to ... with autism make plans and complete complex daily tasks, ... that people with autism can live independent, flexible lives, ... Durham University in England. The researchers compared how ...
Cached Medicine News:Health News:Protein in the brain could be a key target in controlling Alzheimer's 2Health News:Oldest Known Dinosaur Nesting Site Found 2Health News:Protein That Controls Movement Does the Opposite in Parkinson's 2Health News:Researchers discover method to unravel malaria's genetic secrets 2Health News:Kaiser Permanente study finds Gardasil does not trigger autoimmune conditions after vaccination 2Health News:'Inner Dialogue' Might Aid People With Autism 2
... The AlphaPette Pipettor is the ... beyond. Offers accuracy, comfort, and reliability. ... digital volume readout sub-micrometer. Easy interchangeable ... or tiny hands. Adjustable rapid pipet ...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
... Thermo Labsystems was designed specifically to combine ... such as the new fast dial system ... help to define this as a new ... interchangeable handle plate offers a custom fit ...
... In the specialty areas ... or intensive care work, it ... in your practice. Alokas motorized ... Doppler and Tissue Harmonic Echo ...
Medicine Products: